Table 2 Transplant characteristics according to donor type.

From: Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

Characteristics

Total

MSD

MUD

Haplo

P

No. of patients, no. (%)

242

77 (32)

101 (42)a

64 (26)

 

Donor age in years, median (range)

37 (12–68)

48 (12–68)

30 (18–59)

37 (16–67)

<0.0001

ABO blood group mismatch, no. (%)

    

0.2

 Major

48 (20)

14 (18)

27 (27)

7 (11)

 

 Minor

55 (23)

17 (22)

22 (22)

16 (26)

 

Female donor to male recipient, no. (%)

52 (22)

23 (30)

15 (15)

14 (22)

0.2

Donor-recipient CMV serostatus, no. (%)

    

0.002

 Positive/Positive

156 (65)

57 (75)

51 (50)

48 (76)

 

 Positive/Negative

13 (5)

4 (5)

8 (8)

1 (2)

 

 Negative/Positive

60 (25)

11 (15)

38 (37)

11 (18)

 

 Negative/Negative

12 (5)

4 (5)

5 (5)

3 (5)

 

Conditioning regimen, no. (%)

    

0.002

Busulfan-based:

116 (48)

47 (61)

49 (48)

20 (32)

 

 TB3F

53 (22)

2 (3)

29 (28)

8 (13)

 

 TB2F

39 (16)

21 (27)

20 (20)

12 (19)

 

 Bu-Flu

24 (10)

24 (31)

0

0

 

Treosulfan-based:

126 (52)

30 (39)

52 (52)

44 (68)

 

 Treo-Flu

38 (16)

7 (9)

16 (16)

15 (24)

 

 Thio-Treo-Flu

27 (11)

1 (1)

1 (2)

25 (38)

 

 Treo-Flu-Mel

58 (24)

20 (26)

35 (34)

3 (5)

 

 Treo-Flu-TBI

3 (1)

2 (3)

0

1 (1)

 

GvHD prophylaxis, no. (%)

    

<0.0001

 PTCy + Sir + MMF

206 (85)

48 (62)

98 (97)

60 (94)

 

 PTCy + Sir

28 (12)

28 (36)

0

0

 

 PTCy + Sir + /- MMF + ATG

8 (3)

1 (1)

3 (3)

4 (6)

 

Stem cell source, no. (%)

    

0.08

 Bone marrow

6 (3)

1 (1)

1 (1)

4 (6)

 

 Peripheral blood

236 (97)

76 (99)

101 (99)

59 (94)

 

Cell dose infused, median (range)

     

 TNC/Kg x108

7.8 (1.6–35.8)b

7.8 (1.6–35.8)

7.8 (2–17)

8.6 (2.2–28.4)

0.8

 CD34+/Kg x106

6.8 (0.7–23)

6.6 (0.7–18.8)

6.7 (1.2–23)

7 (2.2–13.2)

0.6

 CD3+/Kg x108

2.3 (0.2–7.8)c

2.5 (0.4–7)

2.2 (0.2–7.8)

2.4 (0.3–7.6)

0.1

Median follow-up, months (range)

25 (6–52)

24 (7–50)

19 (6–52)

23 (7–51)

0.3

  1. MSD matched sibling donor, MUD matched unrelated donor, Haplo haploidentical donor, CMV cytomegalovirus, TBF thiotepa, busulfan and fludarabine, Bu-Flu busulfan and fludarabine, Treo-Flu treosulfan and fludarabine, Thio-Treo-Flu thiotepa, treosulfan and fludarabine, Treo-Flu-Mel treosulfan, fludarabine and melphalan, Treo-Flu-TBI treosulfan, fludarabine and TBI 4 Gy, GvHD graft-versus-host disease, PTCy post-transplant cyclophosphamide, Sir sirolimus, MMF mycophenolate mofetil, TNC total nucleated cell.
  2. a16 mismatched unrelated donors (MMUD) are included.
  3. b43 missing.
  4. c31 missing.
Back to article page